U.S. Renewable Energy Stock News

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...

Orange County Bancorp (OBT) has just wrapped up FY 2025 with fourth quarter total revenue of US$31.5 million, basic EPS of US$0.93 and net income of US$12.4 million. This sets the tone for how investors will read the full year against recent momentum in the share price around US$31.40. The company has seen revenue move from US$27.4 million and EPS of US$0.63 in Q4 2024 to US$31.5 million and EPS of US$0.93 in Q4 2025. Trailing twelve month figures sit at US$119.5 million of revenue and EPS of...

Primis Financial's FY 2025 Earnings Snapshot Primis Financial (FRST) closed FY 2025 with fourth quarter revenue of US$78.4 million and basic EPS of US$1.20, while trailing twelve month revenue reached US$211.3 million and EPS came in at US$2.49. Over recent periods, revenue has moved from US$5.8 million in Q4 2024 to US$78.4 million in Q4 2025, and basic EPS has shifted from a loss of US$0.94 per share in Q4 2024 to EPS of US$1.20, putting margins and profitability under closer scrutiny for...

Bicycle Therapeutics (BCYC) has just posted its FY 2025 third quarter numbers, with revenue of about US$11.7 million and a basic EPS loss of US$0.85. Trailing twelve month figures show revenue of roughly US$28.3 million and a basic EPS loss of US$3.62. Over recent quarters, revenue has ranged from US$2.9 million to US$11.7 million, while quarterly basic EPS losses have moved between US$0.74 and US$1.14. This gives investors a clearer sense of a business that appears to be in investment mode...

Atour Lifestyle Holdings (NasdaqGS:ATAT) FY 2025 earnings snapshot Atour Lifestyle Holdings (NasdaqGS:ATAT) has put fresh numbers on the board for FY 2025, with third quarter revenue of C¥2,627.97 million and basic EPS of C¥3.41 anchoring a trailing twelve month EPS of C¥10.62 on revenue of C¥9,086.34 million. The company has seen revenue move from C¥6,669.14 million and trailing EPS of C¥8.46 in the third quarter of 2024 to C¥9,086.34 million and C¥10.62 in the third quarter of 2025, giving...

Bakkt (BKKT) just posted its FY 2025 results with third quarter revenue of US$402.2 million and a basic EPS loss of US$1.02, while trailing twelve month revenue sat at US$3.9 billion against a basic EPS loss of US$5.06. Over recent periods, revenue has ranged from US$214.5 million in Q4 2023 to US$1.8 billion in Q4 2024 and US$1.1 billion in Q1 2025, with EPS swinging between a loss of US$7.25 in Q4 2023 and a profit of US$1.18 in Q1 2025. This gives investors a mixed picture on earnings...

American Vanguard (AVD) opened FY 2025 with mixed results, reporting Q3 revenue of US$119.3 million and a basic EPS loss of US$0.43, while on a trailing twelve month basis revenue stood at US$530.1 million alongside a basic EPS loss of US$3.96. The company has seen quarterly revenue move between US$115.8 million and US$165.6 million over the past six reported quarters, with basic EPS losses ranging from US$0.03 to US$3.21. This highlights pressure on profitability even as the top line remains...

HF Foods Group (HFFG) has just posted its FY 2025 third quarter numbers, with revenue at US$307 million and a basic EPS loss of US$0.02, while on a trailing 12 month basis revenue sits at about US$1.23 billion and basic EPS at a loss of US$0.86. The company has seen quarterly revenue move from US$302 million in Q2 FY 2024 to US$307 million in Q3 FY 2025, with basic EPS shifting across that period from roughly breakeven at US$0.00 in Q2 FY 2024 to a loss of US$0.02 in the latest quarter...

CytomX Therapeutics earnings and Varseta-M data come into focus CytomX Therapeutics (CTMX) is back on radar after reporting full year 2025 results alongside early Phase 1 expansion data for its EpCAM-targeting ADC, Varseta-M, in late-line metastatic colorectal cancer. See our latest analysis for CytomX Therapeutics. The recent Varseta-M data, full year 2025 results and a new shelf registration plus follow-on equity filing have coincided with sharp share price momentum, with a 1 day share...

Iron Mountain (NYSE:IRM) has agreed to acquire ACT Logistics in Australia as part of its global expansion. The company continues to grow its data center segment, adding to its traditional records management operations. Iron Mountain recently raised its dividend by 10%, highlighting its focus on shareholder returns. Iron Mountain, best known for records storage and information management, is in the middle of a meaningful shift in where its business is growing. The ACT Logistics deal broadens...

Invesco, NYSE:IVZ, has introduced an employee benefit that supports new U.S. government "Trump Accounts" under Section 530A child savings accounts. The company plans to match the initial government contribution for eligible children of its employees, adding a private employer layer to the federal program. This move links Invesco's employee benefits directly to a current policy initiative focused on long term child savings. For investors tracking NYSE:IVZ, this new benefit sits alongside a...

Stock performance context for CorMedix Without a specific news catalyst driving fresh headlines, CorMedix (CRMD) continues to draw attention as investors weigh its recent share performance in relation to its role in developing therapies for life threatening conditions. The stock last closed at US$6.54, with returns showing mixed momentum. It recorded a 1.4% gain over the past day, alongside a slight decline over the past week. See our latest analysis for CorMedix. Recent trading tells a mixed...

Silvaco Group (SVCO) surprised the market with quarterly results that came in ahead of expectations, along with revenue guidance above earlier forecasts and cost cuts tracking better than management initially outlined. See our latest analysis for Silvaco Group. Silvaco Group’s recent earnings beat and upbeat guidance have been met with sharp share price momentum, with a 7 day share price return of 53.5% and a year to date share price return of 22%, even though the 1 year total shareholder...

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...

Apellis Pharmaceuticals recently added Mikael Dolsten, M.D., Ph.D., former chief scientific officer of Pfizer, to its board of directors, bringing decades of high-level research and development leadership across major global drug makers. This appointment, alongside growing analyst interest in Apellis’s key products Empaveli and Syfovre, underscores how external experts view the company’s pipeline and commercial portfolio as increasingly relevant in rare kidney disease and eye care...

First Bancorp (NasdaqGS:FBNC) announced the retirement of Michael G. Mayer from his roles as President and CEO of First Bank. Mayer is stepping back from day to day management but will continue to serve on the company’s Board of Directors. The change marks a leadership transition at the top of First Bank’s operating structure. First Bancorp, the holding company for First Bank, operates as a regional banking platform, offering lending, deposit, and related financial services. Leadership...

Terns Pharmaceuticals recently attracted renewed attention after updating its corporate presentation with refreshed pipeline timelines and milestones, while also being selected for inclusion in a STOXX benchmark index effective March 23, 2026. This combination of clearer development visibility, impending index inclusion, and investor focus on the upcoming earnings update has sharpened debate around the company’s long-term prospects and current financial pressures. With investors now closely...

In March 2026, Codexis reported fourth-quarter 2025 results showing revenue of US$38.92 million and net income of US$9.6 million, reversing a prior-year loss and beating analyst expectations, alongside full-year 2025 revenue of US$70.39 million and guidance for 2026 revenue of US$72 million to US$76 million. The quarter was heavily influenced by a large technology transfer agreement with Merck and growing ECO Synthesis platform activity, which also underpins management’s view that existing...

This article examines whether Petco Health and Wellness Company, at around US$3.62, may represent a bargain or a value trap by exploring what the current share price might indicate about the business. The stock has recently experienced sharp moves, with returns of 52.1% over the last 7 days, 44.2% over the last 30 days, 27.0% year to date and 51.5% over the last year. However, the 3 year and 5 year returns show declines of 63.1% and 84.4%, which tells a very different story. These swings...

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...

Earlier this week, Kyivstar Group Ltd. reported its full-year 2025 results, with sales rising to US$1,157 million from US$919 million, even as net income fell to US$124 million from US$283 million and basic EPS from continuing operations declined to US$0.57 from US$1.37. The company also issued 2026 guidance calling for USD revenue growth of 8%–11%, underlining management’s confidence in further expanding its fast-growing digital and connectivity ecosystem despite a volatile operating...